Ironwood Pharmaceuticals (IRWD) EBT (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting $65.2 million for Q1 2026.

• EBT for Q1 2026 came in at $65.2 million, up 279.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.3 million (up 107.21% YoY), and the FY2025 annual result was -$91.1 million, up 10.56% from the prior year.
• EBT came in at $65.2 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$160.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $72.3 million in Q4 2022 to a low of -$1.1 billion in Q2 2023.
• The 5-year median for EBT is $31.9 million (2023), against an average of -$61.8 million.
• Across the five-year window, EBT sank 2100.97% in 2023 and surged 291.62% in 2025, its largest moves.
• Ironwood Pharmaceuticals' EBT stood at $72.3 million in 2022, then slumped by 371.46% to -$196.2 million in 2023, then advanced by 27.06% to -$143.1 million in 2024, then fell by 12.3% to -$160.7 million in 2025, then surged by 140.56% to $65.2 million in 2026.
• The last three EBT figures came in at $65.2 million (Q1 2026), -$160.7 million (Q4 2025), and $68.0 million (Q3 2025), per Business Quant data.